Androxal: Clinically Validated Testosterone Restoration Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.84 | $55.27 (0%) | 🛒 Add to cart |
| 60 | $1.29 | $110.54 $77.38 (30%) | 🛒 Add to cart |
| 90 | $1.11
Best per tab | $165.81 $99.48 (40%) | 🛒 Add to cart |
Similar products
Androxal (enclomiphene citrate) represents a significant advancement in the treatment of male hypogonadism, specifically designed to address secondary hypogonadism by stimulating the body’s endogenous testosterone production. Unlike exogenous testosterone replacement therapies, which can suppress natural hormone synthesis and impair fertility, Androxal works through a selective estrogen receptor modulator (SERM) mechanism to promote the hypothalamic-pituitary-gonadal (HPG) axis. This results in a physiologic increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to restored testosterone levels while preserving or even improving spermatogenesis. It is indicated for adult males with documented hypogonadism who desire to maintain fertility, offering a targeted approach that aligns with the body’s natural endocrine feedback loops.
Features
- Active pharmaceutical ingredient: Enclomiphene citrate
- Mechanism of action: Selective estrogen receptor modulator (SERM)
- Administration: Oral tablet
- Available strengths: 12.5 mg and 25 mg
- Pharmacologic class: Nonsteroidal ovulatory stimulant
- Prescription status: Rx-only
- Half-life: Approximately 5–7 hours
- Bioavailability: High oral absorption
Benefits
- Restores serum testosterone to eugonadal levels through physiologic stimulation of the HPG axis.
- Maintains or improves semen parameters and fertility, a critical advantage over exogenous testosterone.
- Avoids the need for invasive administration routes such as injections, gels, or implants.
- Demonstrates a favorable safety and tolerability profile in clinical studies.
- Supports improvements in libido, energy levels, and mood associated with testosterone deficiency.
- May help preserve bone mineral density and lean muscle mass in hypogonadal men.
Common use
Androxal is primarily prescribed for the treatment of secondary hypogonadism in adult males. This condition is characterized by low testosterone levels due to hypothalamic or pituitary dysfunction, rather than primary testicular failure. Common symptoms prompting evaluation and treatment include fatigue, reduced libido, erectile dysfunction, depressed mood, decreased muscle mass, and loss of bone density. It is particularly suitable for men who wish to preserve fertility, as it avoids the suppressive effects on spermatogenesis seen with traditional testosterone replacement therapy. Patients typically undergo thorough diagnostic evaluation, including measurement of morning total testosterone, LH, FSH, and prolactin levels, to confirm the diagnosis and appropriateness for Androxal therapy.
Dosage and direction
The recommended starting dose of Androxal is 12.5 mg administered orally once daily, preferably in the morning. Dosage may be titrated up to 25 mg once daily based on clinical response and serum testosterone levels measured after 2–4 weeks of therapy. It should be taken with or without food, but consistency in administration relative to meals is advised to maintain stable pharmacokinetics. Treatment duration is individualized based on therapeutic goals and periodic monitoring of testosterone levels, semen analysis (if fertility is a concern), and symptom improvement. Patients should be advised not to crush or split tablets and to adhere strictly to the prescribed regimen unless directed otherwise by their healthcare provider.
Precautions
Prior to initiating Androxal, a comprehensive medical evaluation should be conducted to rule out primary testicular failure, prostate cancer, breast cancer, or other contraindications. Use with caution in patients with a history of depression, hepatic impairment, or thromboembolic disorders. Regular monitoring of testosterone levels, prostate-specific antigen (PSA), hematocrit, and lipid profiles is recommended during treatment. Patients should be informed about the potential for visual disturbances and advised to discontinue use and seek prompt medical attention if blurred vision, scotoma, or photophobia occurs. Androxal is not indicated for use in women or pediatric populations and should be kept out of their reach.
Contraindications
Androxal is contraindicated in patients with known hypersensitivity to enclomiphene citrate or any component of the formulation. It must not be used in individuals with primary testicular failure, pituitary tumors (unless properly treated and monitored), untreated prostate cancer, or breast cancer. Due to its estrogen-modulating effects, it is also contraindicated in patients with active liver disease or unexplained uterine bleeding. Concurrent use with other SERMs or estrogenic therapies is not recommended without careful medical supervision.
Possible side effect
Common adverse reactions reported in clinical trials include headache (∼8%), nausea (∼4%), and dizziness (∼3%). Less frequently, patients may experience hot flashes, insomnia, fatigue, or increased sweating. Visual symptoms such as blurred vision or floaters occur in a small percentage of users and are generally reversible upon discontinuation. Although rare, more serious side effects could include mood changes, thromboembolic events, or allergic reactions. Patients should report any persistent or severe symptoms to their healthcare provider promptly.
Drug interaction
Androxal may interact with medications that affect estrogen pathways or are metabolized by CYP450 enzymes. Concurrent use with testosterone products, anabolic steroids, or other hormonal therapies may diminish its efficacy or lead to unpredictable endocrine effects. Caution is advised when co-administering with drugs known to induce or inhibit CYP3A4, though enclomiphene citrate is primarily metabolized by CYP2D6 and CYP2C19. Patients taking warfarin or other anticoagulants should be monitored closely due to potential changes in coagulation parameters. Always inform the prescribing physician of all current medications, including over-the-counter drugs and supplements.
Missed dose
If a dose of Androxal is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not recommended, as it may increase the risk of adverse effects. Patients should be encouraged to maintain a consistent daily routine to optimize therapeutic outcomes.
Overdose
There is limited clinical experience with Androxal overdose. Symptoms may include exaggerated pharmacologic effects such as severe headache, visual disturbances, nausea, or dizziness. In case of suspected overdose, symptomatic and supportive measures should be instituted. There is no specific antidote; gastric lavage or activated charcoal may be considered if ingestion was recent. Patients should seek immediate medical attention or contact a poison control center for guidance.
Storage
Androxal tablets should be stored at room temperature (20°–25°C or 68°–77°F), in a tightly closed container, and protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local guidelines or drug take-back programs to prevent accidental ingestion or environmental contamination.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or altering any medication regimen. Individual patient responses may vary, and only a licensed medical professional can determine the appropriateness of Androxal based on a comprehensive health assessment. The manufacturer and distributors are not liable for any adverse outcomes resulting from the use or misuse of this product.
Reviews
Clinical studies and patient reports generally reflect positive outcomes with Androxal, particularly regarding its efficacy in raising testosterone levels while preserving fertility. Many users note improvements in energy, sexual function, and overall quality of life. Some individuals report mild and transient side effects, which often resolve with continued use or dose adjustment. Healthcare providers appreciate its targeted mechanism and the advantage it offers over conventional testosterone therapy in appropriate patient populations. Long-term data continue to be collected to further establish its safety and efficacy profile.